THERAPEUTIC EFFECTS OF VYAGHRI JEERAKA AVALEHA IN RESPIRATORY ALLERGIC DISORDERS: A COMPENDIUM REVIEW
AbstractRespiratory Allergic Disorders (RADs), including asthma and allergic rhinitis, are increasingly prevalent, especially among children, and significantly affect quality of life. The limitations of conventional therapies in ensuring long-term relief have prompted the search for alternative remedies. Ayurveda attributes RADs to vitiation of Vata and Kapha doshas and considers impaired immunity due to Ama formation as a key pathological factor. Vyaghri JeerakaAvaleha, an Ayurvedic polyherbal formulation comprising Solanum surattense (Vyaghri), Cuminum cyminum (Jeeraka), Emblica officinalis (Amalaki), and Madhu (Honey), offers a multifaceted approach to the management of RADs. This review compiles pharmacological and Ayurvedic evidence highlighting the formulation’s anti-asthmatic, bronchodilatory, antitussive, anti-inflammatory, and immunomodulatory effects. Vyaghri exhibits bronchodilatory and anti-histaminic properties, while Jeeraka and Amalaki contribute to immune modulation and digestive stimulation, potentially addressing gut dysbiosis often linked with allergies. Madhu enhances bioavailability and contributes anti-inflammatory benefits. Together, these ingredients synergistically work through Rasayana (rejuvenation), Deepana (appetizing), Pachana (digestive), and Vata-Kapha-hara actions to alleviate symptoms and reduce recurrence of RADs. This integrative review supports the potential of Vyaghri JeerakaAvaleha as an effective and sustainable alternative therapy for respiratory allergies by addressing their root cause through immune modulation and systemic detoxification.
Article Information
5
57-64
521 KB
20
English
IJPSR
Parimita Priyadarsani *, Brahm Dutt Sharma and Nisha K. Ojha
Department of Kaumarbhritya, National Institute of Ayurveda, Deemed to be University (De-Novo), Jaipur, Rajasthan, India.
p.parimita111@gmail.com
25 June 2025
18 July 2025
21 July 2025
10.13040/IJPSR.0975-8232.17(1).57-64
01 January 2026





